Bristol Myers Squibb Acquires Forbius

Biogen Acquires Apellis Pharmaceuticals

March 31, 2026

Healthcare Services

Biogen entered into a definitive agreement to acquire Apellis Pharmaceuticals in a ~$5.6 billion cash deal ($41 per share) that also includes contingent value rights (CVRs) tied to SYFOVRE sales performance. The transaction closed in May 2026 and made Apellis a wholly owned subsidiary of Biogen, adding commercial products EMPAVELI and SYFOVRE to Biogen’s immunology/rare disease portfolio and strengthening its expansion into nephrology.

Bristol Myers Squibb to Acquire 2seventy bio in $5.00/share All-Cash Deal

March 25, 2025

Healthcare Services

2seventy bio entered into a definitive merger agreement to be acquired by Bristol Myers Squibb (BMS) for $5.00 per share in an all-cash transaction. The deal is expected to close in the second quarter of 2025, following a tender offer and a second-step merger.

Ajinomoto Co., Inc. Acquires Forge Biologics

November 13, 2023

Biotechnology

Ajinomoto Co., Inc. will acquire Forge Biologics in an all-cash transaction valued at $620 million, expanding Ajinomoto's gene therapy and plasmid/AAV manufacturing capabilities. Forge, a Columbus, Ohio–based viral vector and plasmid CDMO with a 200,000 sq ft cGMP facility and ~300+ employees, will become a consolidated subsidiary to accelerate global gene and cell therapy manufacturing capacity.

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Healthcare Services

Bristol Myers Squibb will acquire Turning Point Therapeutics in a $4.1 billion, all-cash transaction at $76.00 per share under a definitive merger agreement. The deal was originally expected to close in Q3 2022, and the acquisition was completed in August 2022.

Twist Bioscience Acquires Abveris

November 22, 2021

Biotechnology

Twist Bioscience entered into a definitive agreement to acquire Abveris (formerly AbX Biologics), an in vivo antibody discovery services company, for up to $190 million. The deal (approximately $150 million at closing in Twist common stock and up to $40 million contingent stock consideration plus limited cash) is intended to combine Abveris's mouse-based discovery platform with Twist's humanization and antibody engineering capabilities to broaden Twist's antibody discovery and biopharma services.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.